Business
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
Itolizumab-induced reduction of CD6 from T effector cells promotes the development and activity of T regulatory cells CD6-ALCAM pathway confirmed as a target
About this update from Equillium, Inc.
[{"type":"text","content":"\nItolizumab-induced reduction of CD6 from T effector cells promotes the development and activity of T regulatory cells\n\nCD6-ALCAM pathway confirmed as a target to prevent pathogenic T cell recruitment into inflamed organs\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three posters were presented over the weekend at IMMUNOLOGY2022, the annual meeting of The American Association of Immunologists. The meetings are taking place at the Oregon Convention Center in Portland, Oregon, May 6 – 10, 2022.\n\n“Our data suggests that by treating T cells with itolizumab to significantly reduce surface levels of CD6, we are enhancing the potential for T regulatory cell development,” said Dr. Steve Connelly, chief scientific officer at Equillium. “This demonstrates that we are not only able to modulate the immune system by suppressing T effector cells but increasing the potential development and activity of T regulatory cells, resulting in an increased ratio of T regulatory cells to T effector cells. Additional translational data presented by our team suggests that the CD6-ALCAM pathway plays an important role in the migration of T cells through endothelial tissue and demonstrates that blockade of CD6 by itolizumab has the potential to prevent recruitment of pathogenic T cell, such as Th17, into inflamed organs. Collectively, these presentations suggest that the CD6-ALCAM pathway is an attractive target for autoimmune and inflammatory diseases and that itolizumab may be ideally suited to target this pathway.”\n\nItolizumab is a first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating both the activity and trafficking of the pathogenic T cells driving a number of immuno-inflammatory diseases.\n\nDetails of Itolizumab Data Presented\n\nTitle: CD6 – a costimulatory receptor at the nexus of Teff / Treg development\nPresenting Author: Jeanette Ampudia, Scientist, Equillium, Inc.\nPresentation Type: Poster Session\nPoster Number: 532\nSession Title: Immunoregulation-Mechanism of Action\n\nKey Highlights, Summary and Conclusions from Presentation:\n\n\nFirst study to d...